Both NCCN and European Society for Medical Oncology (ESMO) guidelines recommend the detection of FGFR2/3 mutations and fusions in bladder cancer, and the FDA has also approved the therascreen® FGFR RGQ RT-PCR kit as a PCR-based companion diagnostic kit [80, 81]. This evidence concerns the gene FGFR2 and urinary bladder cancer.